Our Strategy

How we performed in FY25 against the iHEALTh strategy

Our Strategy

Move blood products in the value chain in a timely, effective and efficient manner

Ensure 100% of critical consumables are available to support the value chain 100% of the time
Investigate and implement the state of art design for mobile donor vehicles
Optimise process cost efficiency for delivery of blood products

Target achieved / exceeded

Improvement YOY

No concerns yet

Below target

Key Measured Initiatives

Initiative	Target	IR 2023	IR 2024	Progress Apr 2024 – Mar 2025
Driver behaviour score	>=92%	93.2%	93%	93.2%
Blood bank courier fulfilled on time	>=93%	99.3%	98.9%	99.8%
NBI plasma targets met (Litres)	>=177 050 Litres	197 687	190 802	189 119
Manage critical stock levels	>=95%	96.2%	97.30%	96.82%

Provide quality testing in an efficient manner

Harmonise quality standards to meet international benchmarks
SANBS products and services meet the quality control requirements at regulatory bodies and national standards to meet internal and external customer requirements

Target achieved / exceeded

Improvement YOY

No concerns yet

Below target

Key measured initiatives

Initiative	Target	IR 2023	IR 2024	Progress Apr 2024 – Mar 2025
Blood safety index	>=95%	95.6%	95.4%	95.61%
Accreditation	100% SANAS Accreditation	100% SANAS Accreditation	100% SANAS Accreditation	100%
Meet ISO 9001 standards	Fully compliant with ISO 9001 standards	Timeline has been extended due to focus on BECS implementation	Implementation is complete. An independent audit confirmed readiness for formal certification. A service provider has been identified to conduct a formal ISO 9001 certification audit in September 2024	ISO 9001 accreditation achieved
Meet SLA TAT for standard crossmatches	>90% of standard crossmatches completed within agreed SLA TAT of 120 minutes	80.8% Downtime due to loadshedding (placement of generators at Blood Banks is underway)	86.7% Good progress has been made year on year; however, some challenges in meeting targets are attributed to low blood stocks at certain blood banks as well as staff shortages	85.7%
Turnaround time for units to become available for use	>=93%	93.3%	68% The TAT of 42.6% in Q4 and 68.08% year-to-date is due to errors and delays in transmitting results related to the implementation of the BECS system	76.8% The TAT calculation was corrected in November; however, it cannot be backdated to April. As a result, the YTD TAT remains at 76.8% (red). The Q4 TAT of 96.5% provides a more accurate reflection of performance throughout the financial year